Premium
Measurement of Serum α 1 ‐Acid Glycoprotein and cei‐Antitrypsin Desialylation in Liver Disease
Author(s) -
SerbourceGoguel Nathalie,
Corbic Michèle,
Erlinger Serge,
Durand Geneviève,
Agneray Jean,
Feger Jeanne
Publication year - 2007
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840030313
Subject(s) - orosomucoid , glycoprotein , liver disease , alpha (finance) , liver function tests , medicine , ascites , hepatic encephalopathy , cirrhosis , glycan , disease , gastroenterology , immunology , biology , biochemistry , construct validity , nursing , patient satisfaction
To determine whether the presence of circulating desialylated glycoproteins reflect the existence and/or the severity of liver disease, 73 patients were evaluated with liver biopsies, conventional liver function tests, and the measurement of the degree of desialylation of two glycoproteins a x ‐acid glycoprotein (α 1 ‐AGP) and ai‐antitrypsin (α 1 ‐AT). A combination of two immunological methods, available as routine laboratory tests, was used for the determination of the desialylation of α 1 ‐AGP and α 1 ‐AT. The severity of liver disease was assessed by a clinical classification depending upon the presence or absence of four complications (jaundice, ascites, hepatic encephalopathy, and weight loss). The presence of serum desialylated α 1 ‐AGP did not allow detection of mild liver disease, but asialoon‐AGP (and to a lesser extent of asialo‐ai‐(AT) correlated with the severity of liver disease. The sensitivity of desialylated ai‐AGP in detection of severe liver disease was 65%, and its specificity was 80%.